{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-030073","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2026-09-10T20:07:55+00:00","discovered_at":"2026-09-10T20:10:10.205993+00:00","generated_at":"2026-09-10T20:10:18.567448+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CervoMed's neflamapimod Phase 2a nfvPPA data accepted as late-breaking oral at ISFTD 2026","bullets":["Phase 2a trial of neflamapimod in nfvPPA completed enrollment with 25 participants.","12-week biomarker data from first 8 participants accepted as late-breaking oral at ISFTD 2026 (Oct 8-11, Philadelphia).","Presentation will highlight NfL and GFAP biomarker results from at least 22 participants.","nfvPPA has no approved treatments in US or EU; trial conducted at US and UK academic centers."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-030073","json":"https://secwatch.observer/filing/0001437749-26-030073.json","markdown":"https://secwatch.observer/filing/0001437749-26-030073.md","text":"https://secwatch.observer/filing/0001437749-26-030073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926030073/0001437749-26-030073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926030073/crvo20260910_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-10T20:10:18.567448+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}